David MacDonald
Technik-/Wissenschafts-/F&E-Leiter bei XORTX THERAPEUTICS INC.
Profil
David MacDonald is currently the Chief Technology Officer at XORTX Therapeutics, Inc. He previously held positions as President & Chief Executive Officer at Active Pass Pharmaceuticals, Inc., Chief Technology Officer & Vice President at MSI Methylation Sciences, Inc., Section Leader at Hemosol Corp., Staff Researcher at Syntex, Inc., and General Manager at Biovail Contract Research Division.
He also served as the Chief Technology Officer at Immunoflex Therapeutics, Inc. from 2020 to 2021.
Dr. MacDonald obtained a doctorate degree from the University of Alberta.
Aktive Positionen von David MacDonald
| Unternehmen | Position | Beginn |
|---|---|---|
| XORTX THERAPEUTICS INC. | Technik-/Wissenschafts-/F&E-Leiter | 20.01.2022 |
Ehemalige bekannte Positionen von David MacDonald
| Unternehmen | Position | Ende |
|---|---|---|
| Immunoflex Therapeutics, Inc. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2021 |
| Biovail Contract Research Division | Corporate Officer/Principal | - |
Hemosol Corp. /Old/
 Hemosol Corp. /Old/ Pharmaceuticals: MajorHealth Technology Hemosol Inc. is an integrated biopharmaceutical company focused on the development of a portfolio of products based on human hemoglobin. | Corporate Officer/Principal | - |
| Syntex, Inc. | Corporate Officer/Principal | - |
MSI Methylation Sciences, Inc.
 MSI Methylation Sciences, Inc. Pharmaceuticals: MajorHealth Technology MSI Methylation Sciences, Inc. engages in drug development through compound leverage. It focuses on developing pharmaceuticals based on molecules with proven efficacy that are under exploited in pharmaceutical markets. The firm offers s-adenosyl methionine, is a prescription drug used as a dietary supplement. The company was founded by Barry J. Guld and Nancy Harrison in 2006 and is headquartered in Burnaby, Canada. | Präsident | - |
Ausbildung von David MacDonald
| University of Alberta | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| XORTX THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
MSI Methylation Sciences, Inc.
MSI Methylation Sciences, Inc. Pharmaceuticals: MajorHealth Technology MSI Methylation Sciences, Inc. engages in drug development through compound leverage. It focuses on developing pharmaceuticals based on molecules with proven efficacy that are under exploited in pharmaceutical markets. The firm offers s-adenosyl methionine, is a prescription drug used as a dietary supplement. The company was founded by Barry J. Guld and Nancy Harrison in 2006 and is headquartered in Burnaby, Canada. | Health Technology |
Hemosol Corp. /Old/
Hemosol Corp. /Old/ Pharmaceuticals: MajorHealth Technology Hemosol Inc. is an integrated biopharmaceutical company focused on the development of a portfolio of products based on human hemoglobin. | Health Technology |
Active Pass Pharmaceuticals, Inc.
 Active Pass Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Active Pass Pharmaceuticals, Inc. develops drugs for infectious diseases. It engages in the development of drugs that inhibit ABC transporters. The firm also provides portfolio of therapeutic programs, including age-related macular degeneration, travelers' diarrhea, and lipid disorders. The company was founded by Peter B Reiner in 1998 and is headquartered in Vancouver, Canada. | Health Technology |
| Syntex, Inc. | Miscellaneous |
| Biovail Contract Research Division | Commercial Services |
| Immunoflex Therapeutics, Inc. |
